Know Labs Files Appeal to NYSE Commencement of Proceedings to Delist
Know Labs (KNWN) has filed an appeal against NYSE American's decision to delist the company due to its stock price falling below $0.10. During the appeal process, trading of Know Labs stock on NYSE American will be suspended, and the company has transitioned to trading on the OTC Markets under the symbol 'KNWN' effective January 29, 2025.
The company, which specializes in radio frequency dielectric spectroscopy (RFDS), recently initiated a licensing program through Know Labs Technology Licensing (KTL) and continues to advance its proprietary technology. Their primary focus remains on developing non-invasive diagnostics, particularly blood glucose monitoring, which will require FDA clearance before market introduction.
CEO Ron Erickson emphasized that despite the NYSE situation, the company has successfully reduced overhead, received peer-reviewed recognition, and maintains optimism about near-term licensing opportunities and revenue generation.
Know Labs (KNWN) ha presentato un'appello contro la decisione della NYSE American di delistare la società a causa del calo del prezzo delle azioni al di sotto di $0,10. Durante il processo di appello, il trading delle azioni di Know Labs sulla NYSE American sarà sospeso, e la società è passata a negoziare sui OTC Markets con il simbolo 'KNWN' a partire dal 29 gennaio 2025.
La società, specializzata in spettroscopia dielettrica a radiofrequenza (RFDS), ha recentemente avviato un programma di licenze tramite Know Labs Technology Licensing (KTL) e continua a sviluppare la sua tecnologia proprietaria. Il loro obiettivo principale rimane quello di sviluppare diagnosi non invasive, in particolare il monitoraggio della glicemia, che richiederà l'approvazione della FDA prima dell'introduzione sul mercato.
Il CEO Ron Erickson ha sottolineato che, nonostante la situazione della NYSE, la società ha ridotto con successo le spese generali, ha ricevuto riconoscimenti da parte di esperti del settore e mantiene un atteggiamento ottimista riguardo alle opportunità di licenza nel breve termine e alla generazione di entrate.
Know Labs (KNWN) ha presentado una apelación contra la decisión de NYSE American de deslistar a la empresa debido a que su precio de acciones cayó por debajo de $0.10. Durante el proceso de apelación, se suspenderá el comercio de las acciones de Know Labs en NYSE American, y la compañía ha pasado a cotizar en los OTC Markets bajo el símbolo 'KNWN', efectivo a partir del 29 de enero de 2025.
La empresa, que se especializa en espectroscopía dielectrica de radiofrecuencia (RFDS), ha iniciado recientemente un programa de licencias a través de Know Labs Technology Licensing (KTL) y continúa desarrollando su tecnología propietaria. Su enfoque principal sigue siendo el desarrollo de diagnósticos no invasivos, particularmente el monitoreo de glucosa en sangre, lo cual requerirá la aprobación de la FDA antes de la introducción al mercado.
El CEO Ron Erickson enfatizó que, a pesar de la situación en la NYSE, la empresa ha logrado reducir sus gastos generales, ha recibido reconocimiento por parte de revisores independientes y mantiene un optimismo sobre las oportunidades de licencias y generación de ingresos en el corto plazo.
Know Labs (KNWN)는 주가가 $0.10 아래로 떨어져 NYSE American에서 상장폐지 결정을 내린 데 대해 항소를 제기했습니다. 항소 과정 동안 Know Labs 주식 거래는 NYSE American에서 중단되며, 회사는 2025년 1월 29일부터 OTC Markets에서 'KNWN' 기호로 거래되도록 전환했습니다.
회사, 즉 무선 주파수 유전체 분광법 (RFDS)에 특화된 Know Labs는 최근 Know Labs Technology Licensing (KTL)을 통해 라이선스 프로그램을 시작하고 독점 기술을 발전시키고 있습니다. 그들의 주요 초점은 비침습 진단, 특히 혈당 모니터링을 개발하는 것이며, 이는 시장 도입 전에 FDA 승인이 필요합니다.
CEO 론 에릭슨은 NYSE 상황에도 불구하고, 회사가 간접비를 효과적으로 줄였고, 동료 검토 인정도 받았으며, 단기 라이선스 기회와 수익 창출에 대한 낙관적인 입장을 유지하고 있다고 강조했습니다.
Know Labs (KNWN) a déposé un appel contre la décision de la NYSE American de radier l'entreprise en raison de la chute du prix de son action en dessous de $0,10. Pendant le processus d'appel, le commerce des actions de Know Labs sur la NYSE American sera suspendu, et l'entreprise passera à la négociation sur les OTC Markets sous le symbole 'KNWN' à compter du 29 janvier 2025.
L'entreprise, spécialisée dans la spectroscopie diélectrique par radiofréquence (RFDS), a récemment lancé un programme de licences via Know Labs Technology Licensing (KTL) et continue d'avancer dans sa technologie propriétaire. Leur objectif principal reste de développer des diagnostics non invasifs, en particulier le suivi du taux de glucose dans le sang, qui nécessitera une autorisation de la FDA avant l'introduction sur le marché.
Le PDG Ron Erickson a souligné que malgré la situation à la NYSE, l'entreprise a réussi à réduire ses coûts généraux, a reçu une reconnaissance par des pairs et reste optimiste quant aux opportunités de licences à court terme et à la génération de revenus.
Know Labs (KNWN) hat gegen die Entscheidung der NYSE American Berufung eingelegt, das Unternehmen aufgrund des Rückgangs des Aktienkurses unter $0,10 zu delisten. Während des Berufungsverfahrens wird der Handel mit Know Labs-Aktien an der NYSE American ausgesetzt, und das Unternehmen hat ab dem 29. Januar 2025 auf den OTC Markets unter dem Symbol 'KNWN' gewechselt.
Das Unternehmen, das sich auf dielektromagnetische Spektroskopie bei Funkfrequenzen (RFDS) spezialisiert hat, hat kürzlich ein Lizenzierungsprogramm über Know Labs Technology Licensing (KTL) gestartet und entwickelt weiterhin seine proprietäre Technologie. Ihr Hauptaugenmerk liegt auf der Entwicklung von nicht-invasiven Diagnosen, insbesondere der Blutzuckermessung, die vor der Markteinführung eine Zulassung der FDA erfordert.
CEO Ron Erickson betonte, dass das Unternehmen trotz der Situation an der NYSE erfolgreich die Gemeinkosten gesenkt, Anerkennung durch Fachleute erhalten hat und optimistisch in Bezug auf kurzfristige Lizenzmöglichkeiten und Einnahmen ist.
- Recently initiated technology licensing program (KTL) for revenue generation
- Successfully reduced overhead costs
- Received peer-reviewed recognition for their work
- Stock price fallen below $0.10, triggering delisting proceedings
- Trading suspended on NYSE American
- Downgraded to OTC Markets trading
- FDA clearance still required for main product
Insights
The NYSE American's delisting action represents a significant corporate development for Know Labs, with material implications for investors and market dynamics. The transition from NYSE American to OTC Markets (symbol: KNWN) introduces several critical considerations:
The delisting materially impacts trading dynamics through:
- Reduced institutional investor access due to investment mandate restrictions on OTC securities
- Potentially lower trading volume and wider bid-ask spreads, affecting trade execution quality
- Decreased analyst coverage and market visibility
- More stringent broker requirements for trading penny stocks
While management emphasizes positive developments including their technology licensing program and peer recognition, the sub-
From a strategic perspective, Know Labs must now navigate dual challenges: executing its business plan while simultaneously working to meet uplisting requirements. Key metrics for potential NYSE American relisting would include maintaining a share price above
For current shareholders, this transition period requires heightened due diligence. While OTC Markets provides continued trading access, the platform typically experiences reduced liquidity and higher volatility. The company's focus on technology licensing through KTL could provide near-term catalysts, but the delisting adds another layer of complexity to their commercialization journey.
Know Labs Continues Trading as “KNWN” on the OTC Market
In the interim, effective January 29, 2025, FINRA’s Department of Market Operations has assigned the symbol “KNWN” for quotation and trading of the Company’s stock in the over-the-counter market (OTC Markets).
Know Labs’s CEO, Ron Erickson, stated, “It is unfortunate that Know Labs is having to contend with this at a time when it has just initiated a licensing program of its platform technology, continued to receive peer reviewed recognition of our work, successfully reduced overhead, and continued to advance our proprietary technology. We continue to believe the Company has a bright future and the actions of NYSE will in no way deter our commitment to advance the Company’s business plan and increase shareholder value. We remain steadfast in our goal to deliver non-invasive diagnostics to the marketplace with a first focus on blood glucose monitoring. With the recent announcement of Know Labs Technology Licensing (KTL) we look forward to near term opportunities for licensing our platform technology and revenue generation. As we work through the appeal process with the NYSE, we want to thank our shareholders and stakeholders for their support.”
About Know Labs, Inc.
Know Labs, Inc.’s platform technology uses radio frequency spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company’s first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205097196/en/
Know Labs, Inc. Contact:
Investor Relations
T: 206-903-1351
ask@knowlabs.co
Source: Know Labs, Inc.
FAQ
Why is Know Labs (KNWN) being delisted from NYSE American?
Where will KNWN stock trade after NYSE American delisting?
What is Know Labs' main product development focus?
What recent initiatives has KNWN implemented to generate revenue?
Has KNWN appealed the NYSE American delisting decision?
